European delays on HIV prevention drug endanger gay men and others at risk of HIV

Gus Cairns
Published: 18 October 2016

New report shows men seeking out new HIV prevention drug despite government resistance

A new report, PrEP Access in Europe, by the PrEP in Europe Initiative, a coalition of leading HIV organisations that includes NAM, calls on European governments and health authorities to make PrEP (pre-exposure prophylaxis) available to populations at imminent risk of HIV as a matter of urgency.

PrEP means taking HIV drugs, daily or as needed, before possible exposure to HIV in order to prevent infection. Its high level of effectiveness is undisputed. Following US FDA approval in 2012, many countries around the world – including Australia, Brazil, Canada, Kenya, France, Peru, South Africa and Thailand – are in the process of introducing PrEP for people at high risk of HIV into their HIV prevention programming.

According to the European Centre for Disease Control, in 2014 at least 30,000 people were infected in the European Union and 140,000 in the whole of the European region. That’s 80 infections a day in the EU alone. Just over half were among gay men.

Many of these new infections could be averted by the introduction of PrEP; yet to date the only European country in which PrEP is available from the national health system is France. (Editor's note: on 19th October, an announcement was made in Norway that PrEP will be made freely available to groups at risk of HIV through Norway's health service.)

The new report is testimony that PrEP is being actively sought regardless of country approval. It presents for the first time European gay men’s accounts of how they are trying to protect themselves in the absence of action from their governments. The Initiative’s report contains anonymous testimony from men and women in over 30 countries. They use a range of ways to buy or get ‘DIY PrEP’ (Do it Yourself PrEP) outside of official health systems. The report reveals that this ranges from ‘under the counter’ prescriptions from sympathetic doctors to ‘borrowing’ a few pills from HIV-positive friends.

Without official PrEP approval and availability in health care and community settings, gay men risk taking Truvada or even other HIV drugs without knowing their HIV status, STI status, or possible side-effect risk. Many will take PrEP needlessly, or ineffectively. Worse, some will take it when they have just been infected, which risks drug-resistant HIV.

Without clear information about how PrEP works, people from communities most at risk will be unable to use and adhere to PrEP safely and effectively. Furthermore, without country approval and programmes for PrEP, the majority of those who need this highly effective prevention method will not know about it or afford access to it.

With the recent marketing authorisation to Truvada as PrEP by the European Commission, it is now imperative that European member states start introducing PrEP into their HIV prevention programmes, drawing on guidelines already developed by the World Health Organization, the European AIDS Clinical Society and national HIV associations. In addition, accurate information about PrEP needs to be urgently made available to all people at high risk of HIV to ensure they can get PrEP and take it effectively.

NAM has just published a factsheet on how to get PrEP in the UK that provides information on how to go about obtaining PrEP and precautions you can take if buying generic drugs online to ensure that PrEP is safe and effective.

About the PrEP in Europe Initiative

The PrEP in Europe Initiative is a coalition of European organisations and activists concerned with HIV prevention, specifically ensuring access to PrEP (pre-exposure prophylaxis) among people at high risk of HIV.

The Initiative is run by a steering committee of pan-European advocacy organisations including AVAC, NAM/aidsmap, EATG, AIDS Action Europe, NAT and AIDES.

Its mission is threefold: to disseminate up-to-date information on PrEP access in Europe; to influence policymakers and health funders to adopt PrEP in their countries; and to support organisations, groups and individuals advocating for PrEP in their own countries and communities.

European delays on HIV prevention drug endanger gay men and others at risk of HIV

Back
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.